FDA: Page


  • Novartis wins US approval for biosimilar Enbrel

    Erelzi is only the third biosimilar drug approved in the U.S., following copies of Amgen's Neupogen and Johnson & Johnson's Remicade. 

    By Ned Pagliarulo • Aug. 30, 2016
  • Image attribution tooltip
    Roche
    Image attribution tooltip

    Biosim threat stiffens for Roche's Herceptin

    A number of Roche's top-selling cancer drugs face looming competition from biosimilars in both the U.S. and Europe. 

    By Ned Pagliarulo • Aug. 28, 2016
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Theranos planning appeal of federal penalties

    Health regulators last month handed down sweeping sanctions to the blood-testing company, banning founder Elizabeth Holmes from the business for two years. 

    By Ned Pagliarulo • Aug. 26, 2016
  • Sagent recalls injectable antibiotic

    One lot of Oxacillin is being pulled from the market after metal particulate was found in a vial of the drug. 

    By Ned Pagliarulo • Aug. 25, 2016
  • Image attribution tooltip
    FDA
    Image attribution tooltip

    FDA unexpectedly snubs Amgen drug

    Approval had been expected for the drug, a treatment for a type of hormone imbalance in patients with chronic kidney disease. 

    By Ned Pagliarulo • Aug. 25, 2016
  • With PDUFA date for rucaparib set, Clovis eyes rebound

    A high-profile failure of Clovis' lung cancer drug earlier this year had led the company to cut a third of its staff and pin its hopes on rucaparib. 

    By Ned Pagliarulo • Aug. 24, 2016
  • Puma's neratinib closing in on EU market

    European regulators accepted a filing for the biotech's breast cancer drug, despite known gastrointestinal issues caused by the drug. 

    By Suzanne Elvidge • Aug. 23, 2016
  • Amgen refutes 'flawed' cholesterol study

    The big biotech pushes back against a recent medical journal article that criticized its cholesterol drug pricing. 

    By Suzanne Elvidge • Aug. 22, 2016
  • A person stands at a desk in the foyer of an office building.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    FDA delays Sanofi's diabetes combo

    The three-month delay occurred because Sanofi submitted new information about the drug’s pen-delivery device at the FDA’s request, which resulted in a “major amendment” to the original NDA.

    By Kirell Lakhman • Aug. 22, 2016
  • Image attribution tooltip
    FDA
    Image attribution tooltip

    Chinese/Indian manufacturing facilities facing repercussions

    All products coming from the Indian company, Laxachem Organics, are banned from importation into the U.S.

    By • Aug. 18, 2016
  • Another Indian API facility added to EU's 'do not import' list

    German inspectors found close to 35 issues at the Artemis Biotech facility. 

    By • Aug. 18, 2016
  • Avalere: FDA fees are outpacing drug approvals

    Manufacturer's user fees have been increasing, but so has the number of drugs approved. One report says that more can be done to increase efficiency at the FDA. 

    By Lisa LaMotta • Aug. 17, 2016
  • Image attribution tooltip
    Cory Maloy
    Image attribution tooltip

    Ipsen hopes to be David to Allergan's Goliath

    The French biotech is hoping a new indication for its boulinum toxin Dysport will allow it to compete more effectively with Allergan's market-leading Botox. 

    By • Aug. 17, 2016
  • Boehringer seeks real-world data to support reversal agent

    The pharmaceutical company is hoping to bolster sales of Pradaxa with real-wrold data supporting the use of its anti-coagulant reversal agent Praxabind. 

    By • Aug. 16, 2016
  • Chinese regulators advance overhaul of drug manufacturing

    Draft guidelines released last week are a continuation of CFDA's efforts to raise quality standards for domestically produced drugs. 

    By Ned Pagliarulo • Aug. 15, 2016
  • Endo ditches pursuit of abuse-deterrence for Opana

    The specialty pharmaceutical company has withdrawn its sNDA after discouraging discussions with regulators. 

    By Lisa LaMotta • Aug. 15, 2016
  • Image attribution tooltip
    Shire
    Image attribution tooltip

    Shire launches new treatment for hereditary bleeding disorder

    Vonvendi is the first recombinant replacement treatment for von Willebrand disease, a condition with very few treatment options currently on the market.

    By • Aug. 10, 2016
  • Hopes of early end to Lilly breast cancer trial dashed

    The big pharma's CDK 4/6 inhibitor will continue through its Phase 3 program as planned, but Lilly had hoped the trial would be stopped early.

    By Lisa LaMotta • Aug. 10, 2016
  • Pfizer temporarily shutters Indian facility after inspections

    Acquired in last year's Hospira deal, the site near Chennai had previously been flagged by U.S. regulators in 2013 for manufacturing violations. 

    By Ned Pagliarulo • Aug. 9, 2016
  • BIO president defends Orphan Drug Act after op-ed criticism

    Jim Greenwood, president and CEO of BIO, contends that the Orphan Drug Act has been a success, despite recent attacks saying it facilitates high drug pricing. 

    By • Aug. 9, 2016
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Merck locks up another cancer approval for Keytruda

    Merck's latest success comes on the heels of Bristol-Myers Squibb's CheckMate-026 failure in non-small cell lung cancer. 

    By • Aug. 8, 2016
  • Image attribution tooltip
    Novartis
    Image attribution tooltip

    Novartis creeps in on Pfizer's Ibrance

    The Swiss giant's oncology strategy is coming together as a Breakthrough Therapy designation moves it closer to filing on one of its key growth drivers. 

    By Lisa LaMotta • Aug. 4, 2016
  • UK court orders coverage of Gilead's HIV drug in England

    The National Health Service England plans to appeal the decision, claiming it is not responsible for covering preventative treatments.

    By • Aug. 3, 2016
  • Image attribution tooltip
    FDA
    Image attribution tooltip

    Big Pharma benefits more from breakthrough therapy designations: report

    Since the designation was introduced by the FDA in 2012, most of the tagged drugs to reach the market were developed by large pharma companies rather than small biotechs. 

    By • Aug. 2, 2016
  • Teva will provide long-term API contracts to producers in 15 markets

    U.S. regulators set the condition to ensure Teva does not use API supply contracts to force competitors to raise product prices.

    By Edwin Lopez • July 28, 2016